Model Number: CAS 380917-97-5
Type: Auxiliaries and Other Medicinal Chemicals
Grade Standard:Tech Grade
Appearance: Grey solid powde
Perampanel is a selective noncompetitive antagonist of AMPA receptors, the major subtype of ionotropic glutamate receptors. Perampanel was found to be effective in the treatment of refractory partial-onset seizures in three pivotal (Phase 3) clinical trials and has been approved for marketing under the brand name Fycompa by the European Medicines Agency. The drug is currently approved, for the control of partial-onset seizures, in those of both sexes who suffer from epilepsy and who are 12 years of age and older. Perampanel is discontinued.
Packing and Shipping: